ALLMedicine™ Mantle Cell Lymphoma Center
Research & Reviews 4,177 results
https://doi.org/10.1111/bjh.17363
British Journal of Haematology; McCulloch R, Lewis D et. al.
Feb 23rd, 2021 - Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse. We aimed to investigate outcomes and tolerability for ibrutinib when give...
https://doi.org/10.1097/RLU.0000000000003597
Clinical Nuclear Medicine; Xu G, Lu Y
Feb 16th, 2021 - We present here a 72-year-old man with mantle cell lymphoma who has completed chemotherapy and achieved complete metabolic response to the therapy 10 months ago. Series follow-up FDG PET/CT scans have been negative for lymphoma. Current FDG PET/CT...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805322
Blood Advances; Wu W, Wang W et. al.
Feb 11th, 2021 - Inhibition of the B-cell receptor (BCR) signaling pathway is highly effective in B-cell neoplasia through Bruton tyrosine kinase inhibition by ibrutinib. Ibrutinib also disrupts cell adhesion between a tumor and its microenvironment. However, it i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805338
Blood Advances; Maekawa F, Kishimori C et. al.
Feb 11th, 2021 - Truncation of 3' CCND1 by t(11;22) leads to negative SP4 CCND1 immunohistochemistry in blastoid mantle cell lymphoma.|2021|Maekawa F,Kishimori C,Nakagawa M,Takeoka K,Fukutsuka K,|
https://doi.org/10.1016/j.clml.2020.09.007
Clinical Lymphoma, Myeloma & Leukemia; Kumar A, Bantilan KS et. al.
Feb 9th, 2021 - Minimal residual disease (MRD) monitoring has been used to identify early molecular relapse and predict clinical relapse in mantle cell lymphoma (MCL). Few published data exist in MCL on the performance of next-generation sequencing-based assay of...
Guidelines 13 results
https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
FDA
Jul 23rd, 2020 - The Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed ...
https://www.onclive.com/conference-coverage/asco-2020/ktex19-demonstrates-comparable-pharmacologic-clinical-outcomes-to-approved-therapies-in-mcl
May 29th, 2020 - The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial...
http://ascopubs.org/doi/abs/10.1200/JCO.18.00690?journalCode=jco
Gerson,J.,et al
Jan 6th, 2019 - In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our f...
https://doi.org/10.1111/bjh.15283
British Journal of Haematology; McKay P, Leach M et. al.
May 16th, 2018 - Guideline for the management of mantle cell lymphoma.|2018|McKay P,Leach M,Jackson B,Robinson S,Rule S,|therapeutic use,prevention & control,methods,pathology,therapy,
https://doi.org/10.1093/annonc/mdx223
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Campo E et. al.
Sep 8th, 2017 - Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2017|Dreyling M,Campo E,Hermine O,Jerkeman M,Le Gouill S,|diagnosis,genetics,pathology,therapy,standards,
Drugs 25 results see all →
Clinicaltrials.gov 4,543 results
https://doi.org/10.1111/bjh.17363
British Journal of Haematology; McCulloch R, Lewis D et. al.
Feb 23rd, 2021 - Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse. We aimed to investigate outcomes and tolerability for ibrutinib when give...
https://doi.org/10.1097/RLU.0000000000003597
Clinical Nuclear Medicine; Xu G, Lu Y
Feb 16th, 2021 - We present here a 72-year-old man with mantle cell lymphoma who has completed chemotherapy and achieved complete metabolic response to the therapy 10 months ago. Series follow-up FDG PET/CT scans have been negative for lymphoma. Current FDG PET/CT...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805322
Blood Advances; Wu W, Wang W et. al.
Feb 11th, 2021 - Inhibition of the B-cell receptor (BCR) signaling pathway is highly effective in B-cell neoplasia through Bruton tyrosine kinase inhibition by ibrutinib. Ibrutinib also disrupts cell adhesion between a tumor and its microenvironment. However, it i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805338
Blood Advances; Maekawa F, Kishimori C et. al.
Feb 11th, 2021 - Truncation of 3' CCND1 by t(11;22) leads to negative SP4 CCND1 immunohistochemistry in blastoid mantle cell lymphoma.|2021|Maekawa F,Kishimori C,Nakagawa M,Takeoka K,Fukutsuka K,|
https://doi.org/10.1016/j.clml.2020.09.007
Clinical Lymphoma, Myeloma & Leukemia; Kumar A, Bantilan KS et. al.
Feb 9th, 2021 - Minimal residual disease (MRD) monitoring has been used to identify early molecular relapse and predict clinical relapse in mantle cell lymphoma (MCL). Few published data exist in MCL on the performance of next-generation sequencing-based assay of...
News 501 results
https://www.medscape.com/viewarticle/943428
Dec 30th, 2020 - The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory mantle cel...
https://www.medscape.com/viewarticle/939947
Oct 27th, 2020 - Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD. CAR T-cell therapy has demonstrated activity in relapsed/re...
https://www.staging.medscape.com/viewarticle/939270
Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...
https://www.medscape.com/viewarticle/939270
Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...
https://www.staging.medscape.com/viewarticle/937175
Sep 9th, 2020 - Dr Eduardo Sotomayor Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow a watch-and-wait strategy and which should receive aggressive t...